Verition Fund Management
CRNX

Verition Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Verition Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$842K Buy
+22,500
New +$836K ﹤0.01% 1482
2025
Q3 		– Sell
-95,333
Closed -$2.74M – 3794
2025
Q2 		$2.74M Buy
95,333
+68,875
+260% +$2.13M 0.01% 1687
2025
Q1 		$887K Buy
26,458
+9,241
+54% +$345K ﹤0.01% 2209
2024
Q4 		$880K Buy
+17,217
New +$963K ﹤0.01% 2135

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's CRNX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 22,500 shares worth $842K. The stake represents ﹤0.01% of the portfolio and ranks #1482 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in CRNX as recently as Q2 2025.

Verition Fund Management first reported a position in CRNX in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.74M in Q2 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Verition Fund Management held 22,500 shares of Crinetics Pharmaceuticals worth $842K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1482 holding.
  • Verition Fund Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Verition Fund Management's Crinetics Pharmaceuticals position peaked at $2.74M in Q2 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.